Fed. Circ. Won't Let Sandoz Break Into Amgen's Otezla Market
A New Jersey federal judge properly held that Novartis unit Sandoz Inc.'s generic version of Amgen Inc.'s blockbuster psoriasis drug Otezla should be blocked until 2028, the Federal Circuit held Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article